Integra LifeSciences (IART) Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integra LifeSciences in the last twelve months. There are currently 3 sell ratings, 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" IART shares.
View IART analyst ratings or view top-rated stocks.

7 Wall Street analysts have issued 1 year price objectives for Integra LifeSciences' stock. Their IART share price forecasts range from $39.00 to $60.00. On average, they expect the company's share price to reach $47.29 in the next twelve months. This suggests a possible upside of 22.6% from the stock's current price.
View analysts price targets for IART or view top-rated stocks among Wall Street analysts.

Integra LifeSciences' stock was trading at $56.07 at the beginning of the year. Since then, IART stock has decreased by 31.2% and is now trading at $38.56.
View the best growth stocks for 2023 here.

Integra LifeSciences saw a drop in short interest in August. As of August 31st, there was short interest totaling 2,570,000 shares, a drop of 9.2% from the August 15th total of 2,830,000 shares. Based on an average daily trading volume, of 654,400 shares, the days-to-cover ratio is presently 3.9 days. Currently, 3.6% of the shares of the stock are short sold.
View Integra LifeSciences' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 25th 2023.
View our IART earnings forecast.

Integra LifeSciences Holdings Co. (NASDAQ:IART) released its earnings results on Wednesday, July, 26th. The life sciences company reported $0.71 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.57 by $0.14. The life sciences company had revenue of $381.30 million for the quarter, compared to analysts' expectations of $388.79 million. Integra LifeSciences had a net margin of 8.49% and a trailing twelve-month return on equity of 15.60%. The business's quarterly revenue was down 4.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.82 EPS.

ETFs with the largest weight of Integra LifeSciences (NASDAQ:IART) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), First Trust Health Care AlphaDEX Fund (FXH), SPDR S&P Health Care Equipment ETF (XHE), WisdomTree U.S. AI Enhanced Value Fund (AIVL) and Invesco Nasdaq Future Gen 200 ETF (QQQS).iShares U.S. Medical Devices ETF (IHI).

Integra LifeSciences shares split on Tuesday, January 3rd 2017. The 2-1 split was announced on Thursday, December 22nd 2016. The newly minted shares were distributed to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Integra LifeSciences issued an update on its FY 2023 earnings guidance on Thursday, July, 27th. The company provided earnings per share guidance of $3.10-$3.18 for the period, compared to the consensus earnings per share estimate of $3.12. The company issued revenue guidance of $1.55 billion-$1.56 billion, compared to the consensus revenue estimate of $1.56 billion.

173 employees have rated Integra LifeSciences Chief Executive Officer Peter J. Arduini on Glassdoor.com. Peter J. Arduini has an approval rating of 74% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Integra LifeSciences investors own include Boeing (BA), NVIDIA (NVDA), AbbVie (ABBV), Adobe (ADBE), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Intel (INTC), Marvell Technology (MRVL), Alexion Pharmaceuticals (ALXN) and Abbott Laboratories (ABT).

Integra LifeSciences trades on the NASDAQ under the ticker symbol "IART."

Integra LifeSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Shaolin Capital Management LLC (0.00%), Champlain Investment Partners LLC (4.79%), Capital Research Global Investors (4.00%), Alliancebernstein L.P. (3.53%), Clearbridge Investments LLC (3.39%) and Cooke & Bieler LP (3.37%). Insiders that own company stock include Eric Schwartz, Glenn Coleman, Jeffrey Mosebrook, Lisa Evoli, Michael J Mcbreen, Raymond G Murphy, Stuart Essig, Tru St Partnership, LP and Witte Jan De.
View institutional ownership trends.

Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of IART stock can currently be purchased for approximately $38.56.

Integra LifeSciences (NASDAQ:IART) has a market capitalization of $3.14 billion and generates $1.56 billion in revenue each year. The life sciences company earns $180.55 million in net income (profit) each year or $1.57 on an earnings per share basis.

The company employs 3,722 workers across the globe.

Integra LifeSciences' mailing address is 311 ENTERPRISE DRIVE, PLAINSBORO NJ, 08536. The official website for the company is www.integralife.com. The life sciences company can be reached via phone at (609) 275-0500, via email at ir@integralife.com, or via fax at 609-750-4277.